Every week we bring you great information on the latest details of new drugs and new studies on old drugs. In fact in 2018 alone we have had over 20 articles on pharmaceuticals. This plethora of choices and information often overwhelms even the most astute clinician, and when you add …

Therapy offers beneficial weight loss in treatment of diabetes, but which agent in the class leads to the greatest body weight reduction?

Diabetes-status in older Americans can lead experts in establishing an association between cognitive impairment and mortality.

Protecting the heart and helping to reduce mortality, a closer look at beta-adrenoceptor inhibition in diabetes.

Subtle elevations in fasting glucose and triglycerides associated with developing type 2 diabetes.

Study conducted in Germany demonstrates all-cause mortality to be doubled in patients with both diagnosed and undiagnosed type 2 diabetes.

Guest Post by David Kliff, Editor, Diabetic Investor

As I left Vienna after attending the 11th International Conference on Advanced Technologies & Treatments for Diabetes, my thoughts turned to what does this all mean, what was the most significant takeaway? By far the most significant development coming out of ATTD is the long quest to have a REAL closed-loop insulin delivery system is no longer a pipe dream. This is going to happen and for once I believe it will happen in my lifetime. It is difficult to overstate the power of the data I witnessed. The reality here is that some very smart people have come a very long way.

According to a recent study, which one of the following diabetes therapies carries a lower risk for adverse cardiovascular (CV) events? 1. Nonspecific, long-acting sulfonylureas (eg, glyburide and glimepiride) 2. Specific, short-acting sulfonylureas (eg, glipizide, tolbutamide) 3. CV risk does not differ between these agents Follow the link for the answer.

Do you provide any kind of exercise program for your patients? Follow the link to see how you compare to your colleagues.

Dr. Jim McDermott is Vice President of US Medical Affairs for Diabetes at AstraZeneca. He has been with AstraZeneca for more than two decades.